Second, experimentally, this study validated Antrocin’s ability to simultaneously inhibit BRAF, MEK, and PI3K genes present in HCT116 and RKO cell lines, hence its broader anti-tumor effects in CRC, and compared its putative efficacy with that of FDA-approved standard inhibitors. The gene discussed is PIK3CA; the disease is neoplasm.